Address
3 More London Riverside
London, SE1 2RE
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3283 4200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
209
First IPO Date
April 28, 2017
| Name | Title | Pay | Year Born |
| David S. Zaccardelli | President, Chief Executive Officer & Executive Director | 1.37M | 1964 |
| Andrew Fisher | General Counsel | 596,932 | 1970 |
| Kathleen A. Rickard | Chief Medical Officer | 726,000 | 1958 |
| Mark W. Hahn | Chief Financial Officer | 915,915 | 1963 |
| Matthew Casbon | Vice President of Sales, Marketing & Training | 0 | N/A |
| Caroline Diaz | Chief Regulatory Officer | 0 | N/A |
| Ostra Jewell | Senior Vice President of Human Resources | 0 | N/A |
| Kavita Aggarwal | Senior Vice President of Medical Affairs | 0 | N/A |
| Christopher Martin | Chief Commercial Officer | 0 | N/A |
| Tara Rheault | Chief Development Officer | 0 | 1976 |
| Benjamin Harber | Company Secretary | 0 | N/A |
| Victoria Stewart | Senior Director of Investor Relations & Communications | 0 | N/A |
Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.